Nu Skin Enterprises (NUS) EBITDA (2009 - 2026)

Nu Skin Enterprises (NUS) has 18 years of EBITDA data on file, last reported at $4.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 140.65% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $79.7 million (up 146.79% YoY), and the FY2025 full-year result was $65.8 million, up 143.38% from the prior year.
• EBITDA retreated to $4.0 million in Q1 2026, from $23.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $52.1 million in Q1 2022 to a low of -$125.6 million in Q2 2024.
• A 5-year average of $4.5 million and a median of $16.1 million in 2023 frame the typical range for EBITDA.
• Peak annual rise in EBITDA reached 169.15% in 2024, while the deepest fall reached 430.46% in 2024.
• Tracing NUS's EBITDA over 5 years: stood at $27.5 million in 2022, then tumbled by 41.5% to $16.1 million in 2023, then plunged by 430.46% to -$53.1 million in 2024, then surged by 143.79% to $23.2 million in 2025, then tumbled by 82.68% to $4.0 million in 2026.
• Business Quant data shows NUS's EBITDA at $4.0 million in Q1 2026, $23.2 million in Q4 2025, and $21.6 million in Q3 2025.